• Friday, May 07, 2021
  • Last Update : 01:16 pm

India's Cadila Healthcare starts producing own Covid-19 vaccine

  • Published at 11:44 pm April 23rd, 2021
vaccine bangladesh-mehedi
Representational Photo: Mehedi Hasan/Dhaka Tribune

A record rise in Covid-19 infections have led to a public health disaster in the world's 2nd most populous country

India's Cadila Healthcare has started producing its potential Covid-19 vaccine for which it will seek emergency use authorization in May or June, its managing director told Reuters, with an aim to make up to 240 million doses a year.

Government officials have said they are eagerly waiting for Cadila to seek approval for ZyCoV-D soon, as a record rise in coronavirus infections have led to a public health disaster in the world's most populous country after China.

"We have just started producing doses," Sharvil Patel said in a Microsoft Teams interview on Friday. "But it is not meaningfully large."

He said the aim was to produce 10 million doses a month starting June, taking the in-house annual capacity to 120 million. The rest of the production, as required, will mainly come from third-party producers.

"We are already talking with two other manufacturers. We will slowly add more manufacturers," Patel said.

Its DNA plasmid product - which involves the injection of a small part of the virus's genetic code (DNA or RNA) to stimulate immune response in the recipient - is currently meant to be given in three doses but the company is also doing trials on a two-dose regimen, he said.

ZyCoV-D's success is crucial for India, the country with the world's biggest vaccine making capacity.

It exported more than 66 million vaccines before supplies ran tight for its own people as demand surged. The immunisation drive will expand from May 1 though domestic vaccine output will not increase for more than a month.

India is currently using the AstraZeneca shot and homegrown Covaxin. It has also approved Russia's Sputnik V and has urged Pfizer, Moderna and Johnson and Johnson to provide it with vaccines. All those shots will be imported, at least initially.

Patel said unlike some other drugmakers hit by US curbs on exports of vaccine raw material, Cadila was sourcing its ingredients domestically.

"We did anticipate those challenges," he said. "Everything for us is done in India. Our supply chain is secure. We don’t have any issues for the next 14-15 months."

55
Facebook 55
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail